TY - RPRT
KW - Opioid abuse -- Treatment -- Alaska -- Handbooks, manuals, etc
KW - Naltrexone -- Therapeutic use -- Alaska -- Handbooks, manuals, etc
KW - Methadone maintenance -- Alaska -- Handbooks, manuals, etc
KW - Buprenorphine -- Therapeutic use -- Alaska -- Handbooks, manuals, etc
KW - Drug addicts -- Rehabilitation -- Alaska -- Handbooks, manuals, etc
KW - Buprenorphine -- Therapeutic Use
KW - Drug addicts -- Rehabilitation
KW - methadone maintenance
KW - Opioid abuse -- Treatment
KW - Alaska
AU - Alaska Department of Health and Social Services
A1 - 
AB - Introduction -- MAT implementation or expansion -- Getting started -- Billing insurance coverage and telemedicine -- Clinical considerations -- The ASAM criteria -- Screening, assessment and treatment -- Drug testing -- Understanding and preventing Buprenorphine diversion -- Patient communications -- Medications -- Overview of opioid use disorder medications -- Buprenorphine -- Extended-release Naltrexone (Vivitrol) -- Overview of alcohol -- Targeted topics and populations -- Practicing MAT during a public health emergency -- Patients with pain -- Harm reduction and polysubstance use -- MAT in rural Alaska -- Patients with co-occurring mental health disorders -- Hepatitis C treatment -- Pregnancy -- Criminal justice -- Youth -- Appendices -- Abbreviations -- MAT quality planning tool -- Finding substance use disorder treatment in Alaska -- MAT resources
C4 - This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.
C5 - Grey Literature; Education & Workforce; Healthcare Disparities; Opioids & Substance Use
ET - https://alaska.access.preservica.com/uncategorized/io_728dd9a6-0ea3-4acd-86c1-39c6098d9bc7/
LA - English
M1 - Report
N2 - Introduction -- MAT implementation or expansion -- Getting started -- Billing insurance coverage and telemedicine -- Clinical considerations -- The ASAM criteria -- Screening, assessment and treatment -- Drug testing -- Understanding and preventing Buprenorphine diversion -- Patient communications -- Medications -- Overview of opioid use disorder medications -- Buprenorphine -- Extended-release Naltrexone (Vivitrol) -- Overview of alcohol -- Targeted topics and populations -- Practicing MAT during a public health emergency -- Patients with pain -- Harm reduction and polysubstance use -- MAT in rural Alaska -- Patients with co-occurring mental health disorders -- Hepatitis C treatment -- Pregnancy -- Criminal justice -- Youth -- Appendices -- Abbreviations -- MAT quality planning tool -- Finding substance use disorder treatment in Alaska -- MAT resources
PY - 2021
RN - https://alaska.access.preservica.com/uncategorized/io_728dd9a6-0ea3-4acd-86c1-39c6098d9bc7/
T1 - Medications for addiction, treatment guide: Key components for delivering community-based, medications for addiction treatment for opioid use disorders in Alaska. 2nd edition
TI - Medications for addiction, treatment guide: Key components for delivering community-based, medications for addiction treatment for opioid use disorders in Alaska. 2nd edition
U1 - Grey Literature; Education & Workforce; Healthcare Disparities; Opioids & Substance Use
U4 - This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.
U5 - https://alaska.access.preservica.com/uncategorized/io_728dd9a6-0ea3-4acd-86c1-39c6098d9bc7/
Y1 - 2021
ER -